A Survey of Financial Toxicity in Rural Cancer Patients

Sponsor
Dartmouth-Hitchcock Medical Center (Other)
Overall Status
Suspended
CT.gov ID
NCT04032483
Collaborator
(none)
100
1
35.6
2.8

Study Details

Study Description

Brief Summary

This project aims to elucidate the prevalence of financial toxicity, identify significant risk factors for toxicity, and understand the burdens of the specific St. Johnsbury rural population. These data will drive future, larger studies to investigate how to alleviate the burden of financial toxicity, especially in vulnerable patient populations.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    "Financial toxicity" refers to a side effect of cancer treatment that is financial in nature, and has become increasingly important to oncologists, patients, and researchers because of its implications in adverse social outcomes for patients. Financial toxicity in the context of cancer care is the monetary cost, and subsequent social implications of the cost, on patients undergoing cancer treatment. Although financial toxicity for patients undergoing cancer treatment has some research attention, financial toxicity associated with radiation therapy for cancer patients has not. There is preliminary data that has shown that there are two forms of financial toxicity: the direct cost of cancer therapy (medical services) and the indirect costs (gas for travel, lost wages for sick days, etc.). However, the degree of cost and sources have not been fully investigated. Specifically, financial toxicity in the context of cancer patients from rural populations (such as those at NCCC) has not been fully explored. This project will attempt to understand the salient factors, costs, and magnitudes of financial toxicity in radiation therapy that will allow for more targeted studies to investigate vulnerable patient populations who experience greater financial toxicity.

    Study recruitment temporarily halted due to COVID-19.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    A Survey of Financial Toxicity of Radiation Treatment in Rural Cancer Patients
    Actual Study Start Date :
    Jan 8, 2020
    Anticipated Primary Completion Date :
    Dec 28, 2022
    Anticipated Study Completion Date :
    Dec 28, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Financial toxicity [The time frame will once a week for 3-9 weeks, dependent on the treatment duration of the patient.]

      Both qualitative and quantitative surveys will be given to patients and will ask them for their financial information. These surveys will be given each week, on the day the physician sees the patient. The survey will ask for the following information to determine their direct costs of radiation treatment: employment, race, ethnicity, gender, income, insurance status, co-payments, wage-earner status, out-of-pocket costs for treatment, transportation to treatments, and drug costs. The survey will also ask questions to determine their indirect costs of radiation treatment: productivity days lost, disability days, if they have sold anything in the past week, if they have cut down on leisure activities, concern about paying for bills, ability to meet monthly expenses, and how much they deem their cancer treatment has impacted their satisfaction with financial status.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • At least 18 years of age

    • Undergoing treatment at Norris Cotton Cancer Center North, St. Johnsbury, VT

    • Current radiation/oncology patient

    • Ability to speak or write in English

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Norris Cotton Cancer Center Saint Johnsbury Vermont United States 05819

    Sponsors and Collaborators

    • Dartmouth-Hitchcock Medical Center

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nirav.S.Kapadia, Principal Investigator, Dartmouth-Hitchcock Medical Center
    ClinicalTrials.gov Identifier:
    NCT04032483
    Other Study ID Numbers:
    • D19068
    First Posted:
    Jul 25, 2019
    Last Update Posted:
    Feb 8, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 8, 2022